Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dry cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Dry cell. Displaying page 3 of 3.
    « Previous 1  2  3 
    EudraCT Number: 2010-023809-36 Sponsor Protocol Number: GIMEMAAML1310 Start Date*: 2011-10-26
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
    Medical condition: Acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006322-25 Sponsor Protocol Number: SPD602-301 Start Date*: 2012-10-08
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602).
    Medical condition: Patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, beta-thalassemia and Diamond-Blackfan anemia; aquired anemias such as Myelodysplastic Syndrome and o...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002499-16 Sponsor Protocol Number: TMC125-C214 Start Date*: 2006-12-22
    Sponsor Name:Janssen R&D Ireland
    Full Title: Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002843-26 Sponsor Protocol Number: HO132AML/SAKK30/13 Start Date*: 2014-03-27
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients ...
    Medical condition: previously untreated acute myeloid leukemia (AML) or high risk myelodysplasie (MDS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000886 Acute myeloid leukemia LLT
    18.1 100000004864 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Prematurely Ended) LT (Prohibited by CA) SE (Completed) FI (Prematurely Ended) DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004839-23 Sponsor Protocol Number: CA-4948-102 Start Date*: 2023-02-09
    Sponsor Name:Curis, Inc
    Full Title: A Phase 1/2a, Open-Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome a...
    Medical condition: Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001941 AML LLT
    20.0 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003458-13 Sponsor Protocol Number: AFX01_201 Start Date*: 2009-03-18
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Subjects Previously Treated With Epoetin
    Medical condition: Anaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058116 Nephrogenic anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002596-10 Sponsor Protocol Number: INCB54828-203 Start Date*: 2017-01-30
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
    Medical condition: Lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000435-45 Sponsor Protocol Number: Ver-A-T1D Start Date*: 2021-03-24
    Sponsor Name:Medical University of Graz
    Full Title: A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preser...
    Medical condition: Type 1 diabetes mellitus(T1DM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003063-26 Sponsor Protocol Number: 1634 Start Date*: 2023-08-10
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I)
    Medical condition: Newly Diagnosed Medulloblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Trial now transitioned) IT (Prematurely Ended) FR (Prematurely Ended) NL (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004940-27 Sponsor Protocol Number: AIC316-03-II-01(Phase3) Start Date*: 2022-01-05
    Sponsor Name:AiCuris Anti-infective Cures GmbH
    Full Title: A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in ...
    Medical condition: Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004287-30 Sponsor Protocol Number: LAL-CL06 Start Date*: 2014-06-19
    Sponsor Name:Alexion Pharmaceuticals inc
    Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency
    Medical condition: Lysosomal Acid Lipase Deficiency (LALD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10024579 Lysosomal storage disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000780-40 Sponsor Protocol Number: D5740C00002 Start Date*: 2014-11-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
    Medical condition: Anemia in chronic kidney disease patients with dialysis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) SK (Completed) HU (Completed) ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001521-25 Sponsor Protocol Number: NEOMERO-2 Start Date*: 2011-12-15
    Sponsor Name:FONDAZIONE PENTA ONLUS
    Full Title: Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial
    Medical condition: Bacterial meningitis in children up to 90 days of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10004049 Bacterial meningitis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) NL (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003265-17 Sponsor Protocol Number: S63466 Start Date*: 2020-09-10
    Sponsor Name:Universitair Ziekenhuis Leuven (UZ Leuven)
    Full Title: Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FI (Completed) SI (Completed) AT (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 11:20:02 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA